Deerfield Management Company, L.P.

Institutional investor · Portfolio as of Q2 2023

Q2 2023 biggest moves
  • NBIXNBIX

    Neurocrine Biosciences

    Cut 31%

    now 2.4% of portfolio

  • MIRMMIRM

    Mirum Pharmaceuticals

    Sold out

    was 1.1% of portfolio

  • ITCIITCI

    INTRA-CELLULAR THERAPIES

    Sold out

    was 0.9% of portfolio

  • APLSAPLS

    APELLIS PHARMACEUTICALS

    New

    0.6% of portfolio

71 changes in all

Top Holdings101 positions

Checking export access…
Activity:
NUVL
NUVLDelisted

NUVALENT INC

20M$843M18.0%——
8 qtrssince 2021-Q3
Unchanged
0
??
GLAUKOS CORPDelisted
Bond
271.5M$412.7M8.8%——
9 qtrssince 2021-Q2
Decreased
0
VTRS

Viatris Inc.

17.7M$176.7M3.8%$11.56-24.72%
11 qtrssince 2020-Q4
Increased
58
AMED
AMEDDelisted

AMEDISYS INC

1.8M$164M3.5%——
5 qtrssince 2022-Q2
Increased
67
??
NATERA INCDelisted
Bond
101M$146.9M3.1%——
9 qtrssince 2021-Q2
Unchanged
0
AHCO

AdaptHealth Corp.

11.1M$135M2.9%$20.07-39.37%
15 qtrssince 2019-Q4
Increased
54
127.8M$121M2.6%——
5 qtrssince 2022-Q2
Unchanged
0
144.5M$120M2.6%——
10 qtrssince 2021-Q1
Unchanged
0
146M$114.8M2.5%——
3 qtrssince 2022-Q4
Unchanged
0
NBIX

Neurocrine Biosciences, Inc.

1.2M$114.1M2.4%$95.92-1.69%
10 qtrssince 2021-Q1
Decreased
0
CPRX
CPRXDelisted

CATALYST PHARMACEUTICALS INC

8.2M$110.1M2.4%——
4 qtrssince 2022-Q3
Decreased
0
??
ACCOLADE INCDelisted
Bond
122.6M$102.1M2.2%——
5 qtrssince 2022-Q2
Unchanged
0
??
INSMED INCDelisted
Bond
103.2M$98.2M2.1%——
14 qtrssince 2020-Q1
Unchanged
0
DCPH
DCPHDelisted

DECIPHERA PHARMACEUTICALS IN

6.7M$94.4M2.0%——
15 qtrssince 2019-Q4
Increased
64
98.4M$94M2.0%——
4 qtrssince 2022-Q3
Unchanged
0
CNC

Centene Corporation

1.3M$91M1.9%$64.83+4.04%
15 qtrssince 2019-Q4
Increased
58
ACH

Accendra Health, Inc.

4.7M$90.3M1.9%$16.62+14.58%
3 qtrssince 2022-Q4
Increased
57
MRUS
MRUSDelisted

MERUS N V

3M$79.8M1.7%——
7 qtrssince 2021-Q4
Increased
58
SPRY

ARS Pharmaceuticals, Inc.

11.1M$74.2M1.6%$8.53-21.45%
3 qtrssince 2022-Q4
Unchanged
0
89M$63.9M1.4%——
5 qtrssince 2022-Q2
Unchanged
0
$4.7B
AUM
101
Positions
Q2 2023
Filing
HI rating · 1.0/5
Quarterly 13F Value Change
Reported 13F value ($B)
Reported 13F values and quarter-over-quarter reported value changes; not investment returns.
QuarterReported value in US dollarsReported value change
2022-Q1$4,472,946,000-6.17996841585%
2022-Q2$4,848,381,0008.39346149048%
2022-Q3$5,023,740,0003.61685684355%
2022-Q4$4,831,008,337-3.83641794758%
2023-Q1$4,485,670,170-7.14836619832%
2023-Q2$4,684,196,2414.42578396262%
Activity profile
$ moved · Q2'23
New15%Increased24%Decreased22%Exited39%
Composition
Equity vs derivatives
Equity100%Puts0%Calls0%
Holding period
Avg 2.0 years
<1Q11%1-4Q8%1-2Y13%2Y+68%

Deerfield Management Company, L.P. manages $4.7B across 101 positions as of Q2 2023. Top holdings: NUVL (18.0%), GLAUKOS CORP (8.8%), VTRS (3.8%). Fund DNA: Balanced Allocator. HoldingsIntel Score: 1/5.0.

Top holdings by portfolio weight

Total AUM$5B
NUVL18.00%
GLAUKOS CORP8.81%
VTRS3.77%
AMED3.50%
NATERA INC3.14%
AHCO2.88%
IONIS PHARMA2.58%
TABULA RASA 2.56%
BROOKDALE SR2.45%
NBIX2.44%
Other2.35%

Portfolio allocation by GICS sector

Sectors2
Healthcare83.03%
Unknown16.97%

Behavioral investing profile

Checking access…
Balanced Allocator- primarily Healthcare, Unknown
Compare DNA across all funds
7-dimension, SEC 13F-derived research score
Weak(1.0 / 5.0)
Holdings P&L32
Conviction55
Concentration66
Checking access…

Position Outcomes

Best and worst performing positions by estimated return

Cost basis estimates based on full filing history using quarter-end prices. Actual transaction prices are not disclosed in 13F filings.

Accumulation Streaks

Positions with 2+ consecutive quarters of increases - persistent directional conviction.

Security
5Q
BCRXBCRXBioCryst Pharmaceuticals, Inc.
Q3 2025 → Q3 2026+10.8M shares+$87M
3Q
TNGXTNGXTango Therapeutics, Inc.
Q1 2026 → Q3 2026+2.3M shares+$103.5M
2Q
BMRNBMRNBioMarin Pharmaceutical Inc.
Q2 2026 → Q3 2026+1.2M shares+$73.4M
Checking access…

Famous Investors' Portfolios

What the most-followed managers hold, and what they bought and sold each quarter.

Photo credits

Photo:“Warren Buffett at the 2015 SelectUSA Investment Summit”by USA International Trade Administration, cropped,public domainvia Wikimedia Commons

Photo:Leopold Aschenbrenner

Photo:“Cathie Wood ARK Invest Photo”by Caroline Wood, cropped,CC BY-SA 4.0via Wikimedia Commons

Photo:“Valeant Pharmaceuticals' Business Model (headshot)”by Senate Democrats, cropped,CC BY 2.0via Wikimedia Commons

Photo:Harlem Children's Zone

Photo:Mohnish Pabrai

Photo:“Peter Thiel on March 5 2026”by Kantei (The Prime Minister Office of Japan), cropped,CC BY 4.0via Wikimedia Commons

Photo:Charlotte FC

Photo:Ray Dalio

Photo:Himalaya Capital

Photo:Jonathan Kozowyk, Robin Hood

Photo:“Brad Gerstner at the White House 2025 (54581192563)”by The White House, cropped,public domainvia Wikimedia Commons

Photo:SuperReturn North America

Photo:Liz Linder, Harvard Kennedy School

Photo:Oaktree Capital Management

Photo:The Everglades Foundation

Photo:George Soros

Photo:Benjamin Meaker, Point72

Photo:Fundsmith

Photo:“Kenneth C. Griffin photo”by Paul Elledge, cropped,CC BY-SA 4.0via Wikimedia Commons

Data sourced from SEC EDGAR 13F filings. Not financial advice. Full disclaimer

Verify source filings on SEC EDGAR

Optional analytics helps us improve. How it’s used